MRK Merck & Company Inc. (new)

76.48
-1.98  -3%
Previous Close 78.46
Open 77.83
Price To Book 6.13
Market Cap 198876794720
Shares 2,600,376,500
Volume 13,195,229
Short Ratio 4.82
Av. Daily Volume 12,969,948

NewsSee all news

  1. Do Analysts See Any Upside for Ionis Stock?
  2. Understanding Ionis Pharmaceuticals’ Operational Performance
  3. Taking Stock of Ionis’s Performance
  4. Merck Slips After Announcing Acquisition of France's Antelliq Group
  5. [$$] Merck to Buy Animal Health Tech Business for $2.37 Billion

SEC filingsSee all SEC filings

  1. 8-K - Current report 181227104
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163124
  3. 8-K - Current report 181137554
  4. 8-K - Current report 181108479
  5. SC 13G - Statement of acquisition of beneficial ownership by individuals

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date February 16, 2019.
KEYTRUDA - EORTC1325/KEYNOTE-054
Melanoma
Approval announced June 13, 2018.
Keytruda
Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
FDA approval (label expansion) announced June 5, 2018.
KEYTRUDA + chemo (KEYNOTE-021)
First-Line Nonsquamous Non-small cell lung cancer (NSCLC)
Phase 3 trial did not meet primary endpoint - July 24, 2017. Awarded accelerated approval in 2016.
KEYNOTE-040 KEYTRUDA
Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
Tentative approval announced July 20, 2017 - subject to an automatic stay due to a lawsuit from Sanofi claiming patent infringement.
LUSDUNA Nexvue
Diabetes
Phase 3 clinical hold announced July 6, 2017.
KEYTRUDA - KEYNOTE-183
Multiple myeloma
Phase 3 clinical hold announced July 6, 2017.
KEYTRUDA - KEYNOTE-185
Multiple myeloma
Approved Sept. 22, 2017 under accelerated approval in patients undergoing third-line treatment following data from Phase 2 Keynote-59 trial. Phase 3 data released December 14, 2017 in patients undergoing second-line treatment, did not meet the primary endpoint of overall survival, nor did it show a significant improvement in PFS.
Keytruda
Cancer - Third-line Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 1/2 various presentations at ASCO June 5, 2017. Updated data at ESMO Saturday, 9 September 2017 showed ORR 56% in melanoma patients.
Epacadostat with Keytruda - ECHO-202/KEYNOTE-037
NSCLC, RCC, Triple-Negative Breast, Ovarian, Urothelial Carcinoma, Solid Tumors
CRL issued April 7 2017. sNDA for approved drug requested to include data on cardiovascular effects
Januvia (Sitagliptin)
Type 2 Diabetes
Approved March 1, 2017.
Odactra (MK-8237)
House dust mite allergies
FDA Approval announced August 30, 2018.
Doravirine (MK-1439)
HIV
Approved May 18, 2017.
KEYTRUDA
First and Second line locally advanced or metastatic urothelial cancer - bladder cancer
FDA approval announced August 20, 2018.
(MK-3475-189/KEYNOTE-189)
First Line Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Approval announced December 20, 2017.
Ertugliflozin
Type 2 diabetes
Phase 3 interim analysis by DMC advised trial to be discontinued due to lack of benefit vs risk.
MK-8931 (019) - Verubecestat
Mild-to-moderate Alzheimer's
Approval announced November 9, 2017.
Letermovir
Cytomegalovirus (CMV) Infection
Phase 3 trial stopped due to lack of efficacy - February 14, 2017.
MK-8931 (017) - Verubecestat
Mild-to-moderate Alzheimer's
Phase 3 trial met its primary endpoint - October 2016. Updated data presented at ASCO 2017. HR 0.70. OS 10.3 months.
Keytruda - KEYNOTE-045
Bladder Cancer
Phase 3 planned.
Epacadostat with Keytruda
Non-small cell lung cancer (NSCLC)
Phase 3 planned.
Epacadostat with Keytruda -
Bladder cancer
Phase 3 planned.
Epacadostat with Keytruda -
Cancer - squamous cell carcinoma of the head and neck
Phase 3 data due released June 27, 2017. Primary endpoint met but noted August 29, 2017 that key secondary endpoint was not met. Announced October 11, 2017 that it will not seek regulatory approval.
Anacetrapib (MK-0859)
Raising HDL-C and reducing LDL-C
Approved May 10, 2017.
Keytruda
First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
Phase 3 data due 2H 2019 or 1H 2020.
MK-7264
Chronic cough
Approval announced March 14, 2017.
KEYTRUDA
Relapsed or Refractory Classical Hodgkin Lymphoma
PDUFA date March 8, 2017 extended to June 9, 2017 due to submission of extra data. Approved May 23, 2017.
KEYTRUDA
Microsatellite Instability-High Cancer
BLA acceptance announced May 23, 2016 by partner Samsung Bioepis. Approval annuonced April 21, 2017.
RENFLEXIS - SB2 (infliximab biosimilar)
Biosimilar candidate of Remicade
Approval announced May 30, 2017.
ISENTRESS
HIV-1
PDUFA date under priority review 1Q 2019.
Lynparza - SOLO 1
First-line ovarian cancer following platinum-based chemotherapy
Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017 showed HR of 0.58 (42% reduction of risk of disease progression or death). Approval announced January 12, 2018.
Lynparza
Breast cancer
Phase 3 trial did not meet primary endpoint - noted April 6, 2018.
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Approval announced June 12, 2018.
KEYTRUDA
Cervical cancer
Phase 3 data due 1H 2019.
Lynparza
Pancreatic cancer
PDUFA date under priority review January 11, 2019.
Keytruda - KEYNOTE-042
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2020.
Lynparza - OlympiA
HER2-negative breast cancer
FDA approval announced October 30, 2018.
KEYTRUDA + carboplatin-paclitaxel or nab-paclitaxel KEYNOTE-407
Squamous non-small cell lung cancer (sNSCLC)
Phase 3 data due 2H 2019.
Lynparza
Castration-Resistant Prostate Cancer
Approval announced October 5, 2018.
GARDASIL 9
Human Papilloma virus vaccine
Phase 3 data due 2H 2019.
Lynparza + Avastin- PAOLA-1
First-line ovarian cancer
Phase 3 data due 1H 2019.
Keytruda KN-062
Gastric cancer
Phase 3 data due 1H 2019.
Keytruda KN-240
Hepatocellular Carcinoma
Phase 3 data due 4Q 2018.
Keytruda KN-204
Classical Hodgkin Lymphoma
Phase 3 data due 4Q 2018.
Keytruda KN-119
Triple negative breast cancer (TNBC)
Phase 3 data presented at ESMO October 2018. HR 0.61, no difference in PFS.
Keytruda KN-048
Head and Neck Cancer
Phase 3 data due 4Q 2018.
Keytruda KN-522
Triple negative breast cancer (TNBC)
FDA approval announced November 9, 2018.
Keytruda - KEYNOTE-224
Hepatocellular carcinoma (HCC)
FDA approval announced August 16, 2018.
LENVIMA (lenvatinib)
Hepatocellular Carcinoma (HCC)
PDUFA date under priority review for sBLA December 28, 2018.
Keytruda KN-17
Merkel Cell Carcinoma
Phase 3 trial met primary endpoints, demonstrating non-inferiority to meropenem - September 11, 2018.
ZERBAXA(ceftolozane and tazobactam)
Hospital-acquired bacterial pneumonia (HABP)
Phase 1 data at ESMO October 2018 noted zero responses in monotherapy arm, 24% with Keytruda.
MK-1454 - STING
Solid tumors
Phase 3 trial met primary endpoints of PFS and OS.
KEYTRUDA and Inlyta - KEYNOTE-426
Renal cell carcinoma
Phase 3 data due 1H 2020.
Vericiguat
Heart Failure
Phase 3 data due 2H 2019.
Keytruda KN-355
Triple negative breast cancer (TNBC)
Phase 3 data due 2H 2019.
Keytruda KN-181
Esophageal Cancer
Phase 3 data due 2H 2019.
Keytruda KN-177
Colorectal cancer (CRC)
Phase 3 data due 1H 2019.
Keytruda KN-361
Bladder cancer
Phase 3 data due 1H 2019.
Keytruda KN-057
NMIBC Bladder cancer
Phase 3 data due 1H 2019.
Keytruda KN-604
Small cell lung cancer (SCLC)
Phase 3 data due 1H 2020.
LENVIMA (lenvatinib) + Keytruda - KN-581
Renal cell carcinoma (RCC) - cancer
Phase 3 data due 1H 2020.
LENVIMA (lenvatinib) + Keytruda - KN-581
Renal cell carcinoma (RCC) - cancer
Rolling BLA filing has commenced - noted November 13, 2018.
V920
Ebola

Latest News

  1. Do Analysts See Any Upside for Ionis Stock?
  2. Understanding Ionis Pharmaceuticals’ Operational Performance
  3. Taking Stock of Ionis’s Performance
  4. Merck Slips After Announcing Acquisition of France's Antelliq Group
  5. [$$] Merck to Buy Animal Health Tech Business for $2.37 Billion
  6. Stocks - Starbucks, Costco Slump in Premarket; Apple, Merck, Adobe Fall
  7. Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
  8. Merck bolsters animal health unit with $2.4 billion Antelliq purchase
  9. 5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019
  10. Gwynedd Mercy University nearly doubles campus with 154-acre purchase
  11. Today's Research Reports on Trending Tickers: Pfizer and Merck & Co.
  12. Merck to bolster animal health unit with $2.4 billion purchase of Antelliq
  13. Merck to Acquire Privately Held Antelliq Group
  14. J&J's Tremfya Beats Novartis' Cosentyx in Head-to-Head Study
  15. Mallinckrodt's Roxicodone Reformulation Gets CRL From FDA
  16. Lilly Inks Deal With AC Immune for Potential Alzheimer's Drug
  17. 5 Dow Stocks Stand Tall Despite Index's Loss of 2018 Gains
  18. 5 Dow Stocks Defying the Index's YTD Plunge
  19. Merck and Instituto Butantan Announce Collaboration Agreement to Develop Vaccines to Protect Against Dengue Infections
  20. Roche to Create Companion Diagnostic Test for Merck's Keytruda

SEC Filings

  1. 8-K - Current report 181227104
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163124
  3. 8-K - Current report 181137554
  4. 8-K - Current report 181108479
  5. SC 13G - Statement of acquisition of beneficial ownership by individuals
  6. 8-K - Current report 181091636
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 18998577
  8. 8-K - Current report 18973204
  9. 11-K - Annual report of employee stock purchase, savings and similar plans 18907568
  10. 11-K - Annual report of employee stock purchase, savings and similar plans 18907547